drugset / Trial / NCT00474916
Neuropathic Pain in Patients With Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to collect beginning information on whether intravenous (IV) administration of KRN5500 is safe and effective for treatment of neuropathic pain in patients with cancer.
Timeline
- Start
- 2006-06
- Primary completion
- 2009-03
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KRN5500 | Small molecule | 0.6 mg/m2 | Intravenous |
| Subject | KRN5500 | Small molecule | 1.2 mg/m2 | Intravenous |
| Subject | KRN5500 | Small molecule | 1.8 mg/m2 | Intravenous |
| Subject | KRN5500 | Small molecule | 2.2 mg/m2 | Intravenous |